Zobrazeno 1 - 10
of 4 239
pro vyhledávání: '"sacubitril valsartan"'
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 6367-6376 (2024)
Li Zhao,1 Yuanyuan Ren,1 Donghui Qin,2 Xue Yang,1 Zhuo Chen,1 Na Zhang1 1Department of Cardiology, The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161000, People’s Republic of China; 2General Hospital, Qiqihar City Second Hospita
Externí odkaz:
https://doaj.org/article/196cec29b21c43fc95f24121a143e130
Autor:
Uday M. Jadhav, Saumitra Ray, T. Govindan Unni, J. P. S. Sawhney, Ashwani Mehta, Shantanu Guha, Rajiv D. Karnik, Bhupen N. Desai, Aziz Khan, Keyur Patel, Jayesh S. Prajapati, Hitesh J. Shah, Rama Krishna Reddy, Sanjeev Kumar, Soumya Kanti Dutta, Saujatya Chakraborty, Ashfaque Ahmed, Ravi Vishnu Prasad, Gaurav Chaudhary, Amit Kumar, M. Manjappa, Sujal Shetty, Praveen Raja, Vimalraj Bogana Shanmugam
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 4, Pp 663-677 (2024)
Abstract Hypertension, a key modifiable risk factor for cardiovascular diseases (CVD), significantly contributes to premature death and morbidity worldwide. Despite stabilization in age-adjusted global prevalence, the absolute number of hypertensive
Externí odkaz:
https://doaj.org/article/5e5c7848f4ad40caba060bad57eb8e2a
Autor:
Tatsuki Yanagawa, Yuki Asai, Nobuyuki Zakoji, Shingo Hosoe, Yoshihiro Kondo, Shinnosuke Ootsuki, Hidekazu Kato, Maria Aoki, Yoshiaki Yamamoto, Takanori Yamamoto, Masaaki Takahashi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that inhibits the degradation of endogenous natriuretic peptides. Therefore, ARNIs may increase the efficacy of human atrial natriuretic peptide (hANP), a
Externí odkaz:
https://doaj.org/article/f02e5a9fac234225a9d937c12c6f18cf
Autor:
Al Raddadi S, Almutairi M, AlAamer K, Alsalman A, Albalawi M, Almeshary M, Badreldin HA, Almodaimegh H
Publikováno v:
Drug, Healthcare and Patient Safety, Vol Volume 16, Pp 117-124 (2024)
Sultan Al Raddadi,1– 3 Majed Almutairi,1,3 Kholoud AlAamer,1,3 Abdulmahsen Alsalman,3,4 Maram Albalawi,5 Meshary Almeshary,1,3 Hisham A Badreldin,1,2,6 Hind Almodaimegh1– 3 1Department of Pharmaceutical Care, King Abdulaziz Medical City, Ministry
Externí odkaz:
https://doaj.org/article/461d2e197a854eee84e47c8a10f56c46
Autor:
Ludek Pavlu, Marek Vicha, Jakub Flasik, Jana Petrkova, Milos Taborsky, Tereza Kacirkova, Ondrej Holy
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 229-234 (2024)
Background and Aims. There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-
Externí odkaz:
https://doaj.org/article/d1f2b307edac453b86230ed6b0e4aba6
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Autor:
Antoine Garnier-Crussard
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-5 (2024)
Abstract Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk h
Externí odkaz:
https://doaj.org/article/76644807e1c6445890827294846cbe19
Autor:
Mohammad Abumayyaleh, Carina Krack, Jonathan Demmer, Christina Pilsinger, Tobias Schupp, Michael Behnes, Katherine Sattler, Ibrahim El-Battrawy, Nazha Hamdani, Ibrahim Akin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundWomen with heart failure with reduced ejection fraction (HFrEF) often experience worse clinical outcomes compared to men, including higher rates of mortality, hospitalization, and congestion. However, the effects of sacubitril/valsartan on
Externí odkaz:
https://doaj.org/article/08c738bb5ae94d2bbeaed02c4d03d905
Publikováno v:
Contemporary Clinical Trials Communications, Vol 42, Iss , Pp 101303- (2024)
Objectives: To explore the effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in patients with acute myocardial infarction (AMI). Methods: Total of 295 patients with AMI admitted to the hospital were enrolled
Externí odkaz:
https://doaj.org/article/1a0e2d369c4a4e98baec7809f4039d80
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Aims This study aimed to investigate the efficacy and safety of sacubitril/valsartan in abnormal renal function (eGFR < 60 ml/min/1.73m2) patients combined with heart failure based on randomized controlled trials (RCTs) and observational studies.Meth
Externí odkaz:
https://doaj.org/article/d846b857a0704e99a1e6aa3d8ba6f70d